New pill targets KRAS mutation in hard-to-treat cancers
NCT ID NCT04973163
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 26 times
Summary
This early study tests a new daily pill (BI 1823911) for people with advanced solid tumors that have a KRAS G12C mutation, including lung, colorectal, pancreatic, and bile duct cancers. The study aims to find a safe dose and see if the drug, alone or with another KRAS-targeting drug, can shrink tumors. About 30 adults whose cancer has not responded to prior treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS, KRAS MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brussels - HOSP Jules Bordet
Anderlecht/Brussels-Capital, 1070, Belgium
-
Edegem - UNIV UZ Antwerpen
Edegem/Antwerpen, 2650, Belgium
-
Hospital Universitari Vall D Hebron
Barcelona, 08035, Spain
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10021, United States
-
Sarah Cannon Research Institute at Mary Crowley
Dallas, Texas, 75230, United States
-
The Christie
Manchester, M20 4BX, United Kingdom
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
UZ Leuven
Leuven/Vlaams-Brabant, 3000, Belgium
-
Universitair Ziekenhuis Gent
Gent/Oost-Vlaanderen, 9000, Belgium
Conditions
Explore the condition pages connected to this study.